|
| 37029329 | Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. | Breast Cancer Res Treat | 2023 |
| 35005995 | Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. | JCO Precis Oncol | 2022 |
| 35637408 | Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. | Nat Cell Biol | 2022 |
| 36268941 | GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. | Future Oncol | 2022 |
| 34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Cancer Cell | 2021 |
| 33617937 | Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. | Ann Oncol | 2021 |
| 34529000 | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34741023 | Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial. | Nat Commun | 2021 |
| 32485033 | Healthcare use and costs in adult cancer patients with anxiety and depression. | Depress Anxiety | 2020 |
| 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | J Clin Oncol | 2020 |
| 32053137 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. | JAMA Oncol | 2020 |
| 32718986 | Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. | J Immunother Cancer | 2020 |
| 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 33009371 | Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. | Nat Commun | 2020 |
| 32178638 | Age-related differences in breast cancer mortality according to race/ethnicity, insurance, and socioeconomic status. | BMC Cancer | 2020 |
| 30333222 | Breast Cancer Mortality in Older and Younger Patients in California. | Cancer Epidemiol Biomarkers Prev | 2019 |
| 30926636 | Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. | Mol Cancer Ther | 2019 |
| 31058253 | Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. | JCO Precis Oncol | 2019 |
| 30674876 | Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. | Nat Commun | 2019 |
| 30622177 | Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. | Proc Natl Acad Sci U S A | 2019 |
| 29211306 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients. | Cancer | 2018 |
| 28871561 | Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. | Breast Cancer Res Treat | 2017 |
| 28475579 | Prognostic significance of marital status in breast cancer survival: A population-based study. | PLoS One | 2017 |
| 28698973 | Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. | Breast Cancer Res Treat | 2017 |
| 28874753 | Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. | Nat Commun | 2017 |
| 26690931 | Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. | J Community Genet | 2016 |
| 27688295 | Biospecimen Sharing Among Hispanic Women in a Safety-Net Clinic: Implications for the Precision Medicine Initiative. | J Natl Cancer Inst | 2016 |
| 27406347 | Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. | N Engl J Med | 2016 |
| 27406346 | Adaptive Randomization of Neratinib in Early Breast Cancer. | N Engl J Med | 2016 |
| 27185373 | Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. | Clin Cancer Res | 2016 |
| 27009213 | Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. | Mol Cancer Ther | 2016 |
| 26873727 | Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. | Mol Cancer Ther | 2016 |
| 26848768 | Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. | Oncotarget | 2016 |
| 25596748 | Cyclin alterations in diverse cancers: Outcome and co-amplification network. | Oncotarget | 2015 |
| 26275572 | A window-of-opportunity biomarker study of etodolac in resectable breast cancer. | Cancer Med | 2015 |
| 26243651 | Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. | J Oncol Pract | 2015 |
| 26554380 | Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors. | PLoS One | 2015 |
| 26418953 | Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. | Oncotarget | 2015 |
| 26077640 | Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. | Breast Cancer Res Treat | 2015 |
| 25852059 | On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. | Mol Cancer Ther | 2015 |
| 25928476 | Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. | Cell Cycle | 2015 |
| 25950492 | Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. | Cell Cycle | 2015 |
| 25725225 | Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. | Discov Med | 2015 |
| 25725224 | Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. | Discov Med | 2015 |
| 25445424 | Breast cancer in a RAD51D mutation carrier: case report and review of the literature. | Clin Breast Cancer | 2015 |
| 24477977 | Reproductive risk factors and breast cancer subtypes: a review of the literature. | Breast Cancer Res Treat | 2014 |
| 25411317 | Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. | Proc Natl Acad Sci U S A | 2014 |
| 25549704 | Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. | Discov Med | 2014 |
| 25549703 | Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. | Discov Med | 2014 |
| 25593991 | A framework for genomic biomarker actionability and its use in clinical decision making. | Oncoscience | 2014 |